LivaNova launches implantable device for drug-resistant epilepsy

Medical technology company LivaNova has announced the launch of SenTiva Duo, an implantable pulse generator that provides vagus nerve stimulation therapy for patients with drug-resistant epilepsy.

According to a company release, SenTiva Duo has a dual-pin header that provides stimulation in response to rapid heart rate elevations, which can be associated with seizures. The device, which offers the same therapeutic benefits as the original single-pin SenTiva, also logs low heart rate and prone position events and offers day-night and scheduled programming.

“This new offering enables those [vagus nerve stimulation (VNS)] therapy patients with legacy dual-pin systems to have the option to replace their device with SenTiva Duo, delivering the most advanced VNS therapy treatment without the need for lead revision,” James Wheless, MD, professor and chief of pediatric neurology at Le Bonheur Children’s Hospital in Memphis, Tennessee, said in the release. “Having access to SenTiva Duo offers patients therapy that can be customized and delivered automatically, providing optimal seizure control and enabling maximum adherence to treatment.”

SenTiva Duo received 501(k) cleared from the FDA, the release stated, and is available to patients in the U.S.